Marker Therapeutics, Inc.(MRKR)Earnings, Financials & Key Ratios
MRKR•NASDAQ
$1.44
$24M mkt cap·Price updated May 7, 2026
AboutMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.Show more
- Revenue$4M-46.2%
- EBITDA-$12890.43B-115937991.6%
- Net Income-$12163.62B-113346866.3%
- EPS (Diluted)-0.79+33.6%
- EBITDA Margin-99999900%-59280845.1%
- Operating Margin-350.68%-107.9%
- Net Margin-99999900%-61418976.9%
- ROE-144.83%-120.1%
- ROIC-0%
MRKR Key Insights
Marker Therapeutics, Inc. (MRKR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 50.0%
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 70.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MRKR Price & Volume
Marker Therapeutics, Inc. (MRKR) stock price & volume — 10-year historical chart
Loading chart...
MRKR Growth Metrics
Marker Therapeutics, Inc. (MRKR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years50.02%
3 Years0.31%
TTM-46.19%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-99999900%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM24.17%
Return on Capital
10 Years-122.53%
5 Years-54.36%
3 Years-46.62%
Last Year-0%
MRKR Peer Comparison
Marker Therapeutics, Inc. (MRKR) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 ADCT | 478.24M | 3.76 | -3.36 | 14.85% | -173.02% | |||
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 CABA | 409.05M | 4.00 | -2.44 | -121.73% | 0.24 | |||
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ALKT | 1.87B | 17.43 | -37.89 | 32.89% | -10.55% | -13.96% | 0.98 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 |
Compare MRKR vs Peers
Marker Therapeutics, Inc. (MRKR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MRKR Income Statement
Marker Therapeutics, Inc. (MRKR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 183.06K | 205.99K | 213.19K | 466.79K | 1.24M | 3.51M | 3.31M | 6.59M | 3.55M |
| Revenue Growth % | - | 12.53% | 3.5% | 118.95% | 166.01% | 182.96% | -5.76% | 99.06% | -46.19% |
| Cost of Goods Sold | 5.25M | 124M | 12.76M | 18.88M | 3.16M | 11.97M | 10.42M | 13.47M | 0 |
| COGS % of Revenue | 2868.4% | 60194.96% | 5987.41% | 4044.9% | 254.7% | 340.64% | 314.6% | 204.33% | - |
| Gross Profit | -5.07M▲ 0% | -123.79M▼ 2342.6% | -12.55M▲ 89.9% | -18.41M▼ 46.7% | -1.92M▲ 89.6% | -8.45M▼ 340.1% | -7.11M▲ 16.0% | -6.88M▲ 3.2% | 0▲ 100.0% |
| Gross Margin % | -2768.43% | -60094.95% | -5887.41% | -3944.86% | -154.7% | -240.64% | -214.6% | -104.33% | - |
| Gross Profit Growth % | - | -2342.62% | 89.86% | -46.71% | 89.57% | -340.15% | 15.96% | 3.22% | 100% |
| Operating Expenses | 6.41M | 148.38M | 9.98M | 10.47M | 37.56M | 11.34M | 7.48M | 4.24M | 15.98M |
| OpEx % of Revenue | 3502.6% | 72030.25% | 4679.87% | 2243.43% | 3024.62% | 322.64% | 225.78% | 64.35% | 450.68% |
| Selling, General & Admin | 6.41M | 24.38M | 9.98M | 10.47M | 9.76M | 11.34M | 7.48M | 4.24M | 4.18T |
| SG&A % of Revenue | 3502.6% | 11835.3% | 4679.87% | 2243.43% | 786.19% | 322.64% | 225.78% | 64.35% | 99999900% |
| Research & Development | 5.25M | 124M | 12.76M | 18.88M | 27.79M | 11.97M | 10.42M | 13.47M | 11.8T |
| R&D % of Revenue | 2868.4% | 60194.96% | 5987.41% | 4044.9% | 2238.44% | 340.64% | 314.6% | 204.33% | 99999900% |
| Other Operating Expenses | -183K | 116.05M | -12.76M | -18.88M | 0 | -11.97M | -10.42M | -13.47M | -15.98T |
| Operating Income | -11.48M▲ 0% | -148.17M▼ 1190.7% | -22.53M▲ 84.8% | -28.89M▼ 28.2% | -39.48M▼ 36.7% | -19.79M▲ 49.9% | -14.58M▲ 26.3% | -11.12M▲ 23.7% | -12.44M▼ 11.9% |
| Operating Margin % | -6271.03% | -71930.25% | -10567.28% | -6188.29% | -3179.32% | -563.28% | -440.37% | -168.69% | -350.68% |
| Operating Income Growth % | -35.19% | -1190.7% | 84.8% | -28.22% | -36.67% | 49.87% | 26.32% | 23.75% | -11.86% |
| EBITDA | 0 | 0 | -22.42M | -27.81M | -36.32M | -17M | -11.79M | -11.12M | -12.89T |
| EBITDA Margin % | - | - | -10517.97% | -5957.78% | -2924.62% | -483.9% | -356.14% | -168.69% | -99999900% |
| EBITDA Growth % | - | - | - | -24.02% | -30.58% | 53.18% | 30.64% | 5.71% | -99999900% |
| D&A (Non-Cash Add-back) | 11.48M | 148.17M | 105.12K | 1.08M | 3.16M | 2.79M | 2.79M | 2 | 0 |
| EBIT | -11.3M | -147.97M | -22.53M | -28.71M | -41.88M | -19.79M | -14.58M | -11.12M | -12.44M |
| Net Interest Income | 0 | 253.72K | 1.08M | 148.74K | 5.7K | 248.06K | 539.16K | 437.01K | 594.21K |
| Interest Income | 0 | 253.72K | 1.08M | 148.74K | 5.7K | 248.06K | 539.16K | 437.01K | 594.21K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 497.87K | 213.72K | 1.1M | 179.74K | -2.4M | 15.09K | 539.16K | 437.01K | 258.51K |
| Pretax Income | -10.98M▲ 0% | -147.96M▼ 1247.3% | -21.43M▲ 85.5% | -28.71M▼ 34.0% | -41.88M▼ 45.9% | -19.78M▲ 52.8% | -14.04M▲ 29.0% | -10.68M▲ 23.9% | -12.18M▼ 14.0% |
| Pretax Margin % | -5998.99% | -71826.36% | -10050.92% | -6149.73% | -3372.68% | -562.85% | -424.09% | -162.06% | -343.39% |
| Income Tax | 0 | -214K | 0 | 0 | 0 | 0 | 3.67K | 49.95K | -15.16B |
| Effective Tax Rate % | 0% | 0.14% | 0% | 0% | 0% | 0% | -0.03% | -0.47% | 124446% |
| Net Income | -10.98M▲ 0% | -147.96M▼ 1247.3% | -21.43M▲ 85.5% | -28.71M▼ 34.0% | -41.88M▼ 45.9% | -29.93M▲ 28.5% | -8.24M▲ 72.5% | -10.73M▼ 30.3% | -12.16T▼ 113346866.3% |
| Net Margin % | -5998.99% | -71826.36% | -10050.92% | -6149.73% | -3372.68% | -851.87% | -248.76% | -162.82% | -99999900% |
| Net Income Growth % | -347.33% | -1247.28% | 85.52% | -33.97% | -45.89% | 28.53% | 72.48% | -30.28% | -99999900% |
| Net Income (Continuing) | -10.98M | -147.96M | -21.43M | -28.71M | -41.88M | -19.78M | -14.05M | -10.73M | -12.16T |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -10.15M | 5.81M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -11.62▲ 0% | -77.50▼ 567.0% | -4.70▲ 93.9% | -6.10▼ 29.8% | -5.47▲ 10.3% | -3.58▲ 34.6% | -1.93▲ 46.1% | -1.19▲ 38.3% | -0.79▲ 33.6% |
| EPS Growth % | -251.06% | -566.95% | 93.94% | -29.79% | 10.33% | 34.55% | 46.09% | 38.34% | 33.61% |
| EPS (Basic) | -11.62 | -77.50 | -4.70 | -6.10 | -5.47 | -3.58 | -1.93 | -1.19 | -0.79 |
| Diluted Shares Outstanding | 945.35K | 1.91M | 4.56M | 4.7M | 7.65M | 8.35M | 8.81M | 8.98M | 15.31M |
| Basic Shares Outstanding | 945.35K | 1.91M | 4.56M | 4.7M | 7.65M | 8.35M | 8.81M | 8.98M | 15.31M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
MRKR Balance Sheet
Marker Therapeutics, Inc. (MRKR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.18M | 62M | 45.49M | 24.41M | 45.98M | 16.62M | 17.13M | 22.02M | 19.07T |
| Cash & Short-Term Investments | 5.13M | 61.75M | 43.9M | 21.35M | 42.35M | 11.78M | 15.11M | 19.19M | 16.07T |
| Cash Only | 5.13M | 61.75M | 43.9M | 21.35M | 42.35M | 11.78M | 15.11M | 19.19M | 16.07T |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 108.18K | 56.19K | 1M | 237 | 2.4M | 1.03M | 2.35M | 1.37M |
| Days Sales Outstanding | - | 191.68 | 96.2 | 782.38 | 0.07 | 249.53 | 113.3 | 129.96 | 140.89 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -988.13K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 141.72K | 1.53M | 0 | 1.15M | 585.84K | 988.13K | 0 | 3T |
| Total Non-Current Assets | 0 | 148K | 872.7K | 21.2M | 22.15M | 17.8M | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 148K | 872.7K | 21.2M | 22.15M | 17.8M | 0 | 0 | 0 |
| Fixed Asset Turnover | - | 1.39x | 0.24x | 0.02x | 0.06x | 0.20x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 143 | 0 | 0 | 0 |
| Total Assets | 5.18M▲ 0% | 62.14M▲ 1099.6% | 46.36M▼ 25.4% | 45.61M▼ 1.6% | 68.14M▲ 49.4% | 34.42M▼ 49.5% | 17.13M▼ 50.2% | 22.02M▲ 28.6% | 19.07T▲ 86596268.5% |
| Asset Turnover | 0.04x | 0.00x | 0.00x | 0.01x | 0.02x | 0.10x | 0.19x | 0.30x | 0.00x |
| Asset Growth % | -34.6% | 1099.6% | -25.4% | -1.61% | 49.37% | -49.48% | -50.24% | 28.58% | 86596268.5% |
| Total Current Liabilities | 1.52M | 2.8M | 1.99M | 6.4M | 12.9M | 7.78M | 3.07M | 3.46M | 2.27T |
| Accounts Payable | 1.01M | 1.62M | 993K | 2.94M | 5.14M | 1.1M | 961K | 1.07M | 793.73K |
| Days Payables Outstanding | 70.55 | 4.77 | 28.39 | 56.74 | 593.67 | 33.58 | 33.67 | 28.89 | - |
| Short-Term Debt | 5K | 0 | 204.13K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 493K | 0 | 0 | 0 | 1.15M | 2.5M | 0 | 0 | 974.8B |
| Other Current Liabilities | 166.31K | 465.57K | 472.68K | 1.69M | 2.05M | 2.93M | 1.84M | 86.95K | 1.3T |
| Current Ratio | 3.40x | 22.11x | 22.83x | 3.81x | 3.56x | 2.14x | 5.57x | 6.36x | 8.39x |
| Quick Ratio | 3.40x | 22.11x | 22.83x | 3.81x | 3.56x | 2.14x | 5.89x | 6.36x | 8.39x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.02M | 1.62M | 280.25K | 11.87M | 11.25M | 7.04M | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 280.25K | 11.87M | 11.25M | 7.04M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.52M | 2.8M | 2.27M | 18.27M | 24.15M | 14.82M | 3.07M | 3.46M | 2.27T |
| Total Debt | 5K | 0 | 484.38K | 12.26M | 11.87M | 7.62M | 0 | 0 | 0 |
| Net Debt | -5.12M | -61.75M | -43.42M | -9.1M | -30.48M | -4.17M | -15.11M | -19.19M | -16.07T |
| Debt / Equity | 0.00x | - | 0.01x | 0.45x | 0.27x | 0.39x | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | 3.66M▲ 0% | 59.34M▲ 1522.2% | 44.09M▼ 25.7% | 27.34M▼ 38.0% | 43.99M▲ 60.9% | 19.6M▼ 55.4% | 14.05M▼ 28.3% | 18.56M▲ 32.1% | 16.8T▲ 90507748.6% |
| Equity Growth % | -40.85% | 1522.16% | -25.71% | -37.97% | 60.86% | -55.44% | -28.31% | 32.06% | 90507748.57% |
| Book Value per Share | 3.87 | 31.08 | 9.67 | 5.81 | 5.75 | 2.35 | 1.60 | 2.07 | 999999.00 |
| Total Shareholders' Equity | 3.66M | 59.34M | 44.09M | 27.34M | 43.99M | 19.6M | 14.05M | 18.56M | 16.8T |
| Common Stock | 10.62K | 45.44K | 45.73K | 50.73K | 8.31K | 8.41K | 8.89K | 10.71K | 16.67B |
| Retained Earnings | -157.42M | -306.11M | -327.53M | -356.24M | -398.12M | -428.05M | -436.29M | -447.02M | -459.18T |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MRKR Cash Flow Statement
Marker Therapeutics, Inc. (MRKR) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.44M | -14.48M | -18.28M | -20.03M | -27.28M | -26.97M | -16.44M | -10.91M | -12.01T |
| Operating CF Margin % | -4610.1% | -7029.29% | -8576.36% | -4292.06% | -2196.95% | -767.66% | -496.51% | -165.53% | -99999900% |
| Operating CF Growth % | -29.64% | -71.57% | -26.27% | -9.57% | -36.16% | 1.13% | 39.05% | 33.64% | -99999900% |
| Net Income | -10.98M | -147.96M | -21.43M | -28.71M | -41.88M | -19.78M | -14.05M | -10.73M | -12.16T |
| Depreciation & Amortization | 0 | 0 | 286.58K | 1.08M | 3.16M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.74M | 16.35M | 5.36M | 5.23M | 5.96M | 0 | 858.27K | 245.86K | 537.54B |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -497.87K | 116.08M | -18K | -31K | 0 | -2.43M | -6.1M | 0 | -388B |
| Working Capital Changes | 302.37K | 1.04M | -2.48M | 2.4M | 5.47M | -4.76M | 2.85M | -424.87K | -388K |
| Change in Receivables | 0 | 0 | 51.99K | 55.63K | 1M | -2.4M | 1.37M | -1.32M | 977.3K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 283.37K | 1.24M | -963.97K | 0 | 0 | -1.32M | 611.26K | 8.76K | -454.57K |
| Cash from Investing | 0 | -147.67K | -374.98K | -9.25M | -3.13M | -4.95M | 18.66M | 0 | 0 |
| Capital Expenditures | 0 | -147.67K | -374.98K | -9.25M | -3.13M | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | 71.69% | 175.89% | 1982.26% | 252.16% | 0% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -4.95M | 18.66M | 0 | 0 |
| Cash from Financing | 5.72M | 71.25M | 816.48K | 6.74M | 52.56M | 202.13K | 1.11M | 14.99M | 9.86T |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 816.48K | 1000K | 1000K | 202.13K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -310.49K | -71.71K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 619.62K | 4.37M | 0 | 550K | 3.09K | 0 | 90.48K | 62.16K | 9.86T |
| Net Change in Cash | -2.72M▲ 0% | 56.62M▲ 2180.0% | -17.84M▼ 131.5% | -22.55M▼ 26.4% | 22.14M▲ 198.2% | -31.72M▼ 243.2% | 3.33M▲ 110.5% | 4.08M▲ 22.6% | -2.15T▼ 52673421.9% |
| Free Cash Flow | -8.44M▲ 0% | -14.63M▼ 73.3% | -18.66M▼ 27.6% | -29.29M▼ 57.0% | -30.41M▼ 3.8% | -26.97M▲ 11.3% | -16.44M▲ 39.0% | -10.91M▲ 33.6% | -12.01T▼ 110116529.0% |
| FCF Margin % | -4610.1% | -7100.98% | -8752.25% | -6274.32% | -2449.11% | -767.66% | -496.51% | -165.53% | -99999900% |
| FCF Growth % | -29.64% | -73.32% | -27.56% | -56.96% | -3.84% | 11.31% | 39.05% | 33.64% | -99999900% |
| FCF per Share | -8.93 | -7.66 | -4.09 | -6.23 | -3.97 | -3.23 | -1.87 | -1.21 | -784721.16 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.10x | 0.85x | 0.70x | 0.65x | 0.90x | 2.00x | 1.02x | 0.99x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MRKR Key Ratios
Marker Therapeutics, Inc. (MRKR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -39.7% | -223.15% | -469.72% | -41.44% | -80.37% | -117.42% | -94.14% | -48.95% | -65.81% | -144.83% |
| Return on Invested Capital (ROIC) | - | - | - | - | -229.06% | -186.5% | -102.59% | -152.14% | - | -0% |
| Gross Margin | - | -2768.43% | -60094.95% | -5887.41% | -3944.86% | -154.7% | -240.64% | -214.6% | -104.33% | - |
| Net Margin | - | -5998.99% | -71826.36% | -10050.92% | -6149.73% | -3372.68% | -851.87% | -248.76% | -162.82% | -99999900% |
| Debt / Equity | 0.00x | 0.00x | - | 0.01x | 0.45x | 0.27x | 0.39x | - | - | - |
| FCF Conversion | 2.65x | 0.77x | 0.10x | 0.85x | 0.70x | 0.65x | 0.90x | 2.00x | 1.02x | 0.99x |
| Revenue Growth | - | - | 12.53% | 3.5% | 118.95% | 166.01% | 182.96% | -5.76% | 99.06% | -46.19% |
MRKR Frequently Asked Questions
Marker Therapeutics, Inc. (MRKR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Marker Therapeutics, Inc. (MRKR) reported $3.5M in revenue for fiscal year 2025. This represents a 2838% increase from $0.1M in 1999.
Marker Therapeutics, Inc. (MRKR) saw revenue decline by 46.2% over the past year.
Marker Therapeutics, Inc. (MRKR) reported a net loss of $12.16T for fiscal year 2025.
Dividend & Returns
Marker Therapeutics, Inc. (MRKR) has a return on equity (ROE) of -144.8%. Negative ROE indicates the company is unprofitable.
Marker Therapeutics, Inc. (MRKR) had negative free cash flow of $12.01T in fiscal year 2025, likely due to heavy capital investments.
Explore More MRKR
Marker Therapeutics, Inc. (MRKR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates